




Vol. 38, No. 1  
FEBRUARY, 2004

# *The Bovine* **PRACTITIONER**

THE OFFICIAL PUBLICATION OF THE  
AMERICAN ASSOCIATION OF BOVINE PRACTITIONERS



© Copyright American Association of Bovine Practitioners; open access distribution.

## **37th ANNUAL CONVENTION**

American Association of Bovine Practitioners  
Fort Worth, Texas  
September 23-25, 2004

# RESEARCH LEADS TO

© Copyright American Association of Bovine Practitioners; open access distribution.

## Bovi-Shield® GOLD™. The New Standard.

Extensive research has led to a reproductive and respiratory vaccine line like no other. With Bovi-Shield GOLD, Pfizer science offers you new levels of protection, safety and flexibility.

## Bovi-Shield GOLD—Research-Proven Advantages.

- Unique new BVD Type 2 strain<sup>1</sup>.
- Unprecedented BVD fetal protection—Types 1 & 2<sup>2</sup>.
- Excelled against an extreme BVD Type 2 challenge model no other vaccine manufacturer has attempted<sup>3</sup>.
- Only vaccines to stop IBR abortion<sup>2</sup>.
- Modified-live viral (MLV) vaccine safe for use in pregnant cows.\*
- MLV safe for use in nursing calves\*.
- New 12-month duration of safety.
- Unique patent-pending non-recombination technology.



*Bovi-Shield GOLD FP™—protection against IBR abortion and persistent infection from BVD Types 1 & 2 means more live calves.*

<sup>1</sup>Animal Health Laboratory, Laboratory Services Division, University of Guelph.

<sup>2</sup>Bovi-Shield GOLD FP™ and PregGuard® GOLD™ FP™ 10 products only.

<sup>3</sup>Data on File, Study 3131R-60-02-258, Pfizer Inc.

<sup>4</sup>Data on File, Study 2134H-60-02-023, Pfizer Inc.

<sup>5</sup>Data on File, Study 2434H-60-02-048, 049, 050, Pfizer Inc.

Bovi-Shield® and PregGuard® are registered trademarks and Bovi-Shield GOLD™, Bovi-Shield FP™, PregGuard GOLD™, PregGuard FP™, Beef Friendly™ and Gain everything. Sacrifice nothing™ are trademarks of Pfizer Inc.

©2003 Pfizer Inc. BSD03203

**\*Label indications:** The Bovi-Shield GOLD line and PregGuard GOLD FP 10 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with the Bovi-Shield FP line or the Bovi-Shield GOLD FP line prior to breeding initially and within 12 months thereafter. The Bovi-Shield GOLD line of products may also be administered to calves nursing pregnant cows provided their dams were vaccinated prior to breeding as described above.



Animal Health



# GOLD!

© Copyright American Association of Bovine Practitioners; open access distribution.

## Bovi-Shield GOLD FP—Unprecedented BVD Type 2 Fetal Protection

- 100% blockage of virus in blood of heifers<sup>4</sup>.
- 100% blockage of virus in fetal fluids.
- 100% protection from birth of persistently infected (PI) calves.


## Unrivalled Respiratory Protection

Bovi-Shield GOLD excelled against an extreme BVD Type 2 challenge model no other vaccine manufacturer has attempted<sup>3</sup>.

## New Levels of Safety & Convenience

- Repeated safety trials in thousands of pregnant cows have proven the safety of Bovi-Shield GOLD<sup>5</sup>.
- New 12-month duration of safety means you can vaccinate when it's convenient for you\*.
- New technology circumvents recombination risk.

### Bovi-Shield GOLD Protection



For more information, contact your sales representative. Or visit [www.bovi-shieldgold.com](http://www.bovi-shieldgold.com)

**NEW Bovi-Shield® GOLD™**

**Gain everything. Sacrifice nothing.™**

# THERE'S A BAD GUY OUT THERE.



Hardjo-bovis has been devastating to reproduction. Now, you can do something about it.




*Leptospira*

Introducing Spirovac™, the only vaccine that stops lepto hardjo-bovis, the most important bovine leptospire in the United States.<sup>1</sup> Finally, you can prevent the disease that's causing infertility and early embryonic death, resulting in lower conception rates.

Standard L5 vaccines are not effective against hardjo-bovis. Only Spirovac delivers proven, comprehensive and safe protection.

- Stops shedding and bacterial colonization in the urinary and reproductive tracts, dramatically reducing bacterial exposure.
- Offers a full 12 months of protection, for less labor and greater peace of mind.
- Strong placental and fetal protection helps prevent long-term maintenance host infections.
- Safe for calves as young as four weeks, allowing protection before greatest risk.
- Stimulates a vigorous cell-mediated immunity (CMI) response.



**NEW**

**Spirovac™**

**The only protection against hardjo-bovis.™**



**Animal Health**

[www.spirovac.com](http://www.spirovac.com)

With research confirming hardjo-bovis in more than 50 percent of U.S. dairy operations,<sup>1</sup> Spirovac can have a significant, positive effect on your clients' businesses. Add it to your current L5 vaccination regimen—because there's only one way to stop hardjo-bovis.

**For more details, contact your Pfizer representative.**

**PREVENTS BACTERIAL COLONIZATION ~ STOPS SHEDDING ~ PROVEN 12-MONTH PROTECTION**

© 2003 Pfizer Inc. Spirovac™ is a trademark of CSL Ltd, Australia. The only protection against hardjo-bovis.™ is a trademark of Pfizer Inc. SPV02013. Association of U.S. Dairy Producers and Veterinarians.



# The Bovine PRACTITIONER

**EDITOR:**  
**ROBERT A. SMITH, DVM**  
3404 Live Oak Lane  
Stillwater, Oklahoma 74075  
Tel: (405) 372-8666  
FAX (405) 743-8422

**PRINTER:**  
**Frontier Printers, Inc.**  
205 W. 9th  
Stillwater, Oklahoma 74074

## OFFICERS

<b>President</b> .....	<b>Mark Spire, DVM</b> Manhattan, Kansas
<b>President-Elect</b> .....	<b>Rich Meiring, DVM</b> Marysville, Ohio
<b>Vice President</b> .....	<b>John Ferry, DVM</b> Belleville, New York
<b>Past President</b> .....	<b>Patty Scharko, DVM</b> Lexington, Kentucky
<b>Executive Vice President</b> .....	<b>James A. Jarrett, DVM</b> Rome, Georgia
<b>Treasurer</b> .....	<b>Mark Wustenberg, DVM</b> Bay City, Oregon
<b>Parliamentarian</b> .....	<b>M. Gatz Riddell, DVM</b> Auburn, Alabama

## BOARD OF DIRECTORS

<b>Roger Saltman, DVM</b> Cazenovia, New York 1st District, 2005	<b>Andy Johnson, DVM</b> Seymour, Wisconsin 5th District, 2006	<b>Alan Herring, DVM</b> Litchfield Park, Arizona 10th District, 2005
<b>Darcie J. Stolz, DVM</b> Strasburg, Pennsylvania 2nd District, 2006	<b>Steve Stewart, DVM</b> Woodbury, Minnesota 6th District, 2004	<b>Scott Waltner, DVM</b> Eagle, Idaho 11th District, 2006
<b>Charlie Hatcher, DVM</b> College Grove, Tennessee 3rd District, 2004	<b>Wade Taylor, DVM</b> Oakley, Kansas 7th District, 2005	<b>Reny Lothrop, DVM</b> Cambridge, Ontario, Canada 12th District, 2004
<b>Michael Bolton, DVM</b> Greenville, Michigan 4th District, 2005	<b>Charlie E. Deyhle, Jr., DVM</b> Canyon, Texas 8th District, 2006	<b>Sjoert Zuidhof, DVM</b> Lethbridge, Alberta, Canada 13th District, 2005
	<b>Jim Wasson, DVM</b> Armour, South Dakota 9th District, 2004	

## REPRESENTATIVE TO THE AVMA HOUSE OF DELEGATES:

**Darrel E. Johnson, DVM**  
Weyauwega, Wisconsin

**James A. Jarrett, DVM**  
(alternate)

## EXHIBITS MANAGER:

**Samuel Hutchins, III, DVM**  
South Barre, Vermont

## ADVERTISING AGENCY:

**J. T. O'Brien & Assoc.**  
12118 Nieman Road  
Overland Park, KS 66213  
913-402-8383 Fax: 913-897-9047

THE BOVINE PRACTITIONER is published by the American Association of Bovine Practitioners, Inc., at **Frontier Printers, 205 W. 9th, Stillwater, OK 74074 (Tel: 405-372-8500; FAX 405-372-8523)**. Over 6000 copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to:

**Dr. James A. Jarrett, Exec. Vice President, AABP, P.O. Box 1755, Rome, GA 30162-1755**

**Tel: 1-800-269-2227; FAX 706-232-2232**

**e-mail: aabphq@aabp.org**

**http://www.aabp.org**

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in February and June annually. It also serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English.

Copies of THE BOVINE PRACTITIONER are available to non-members for \$25.00 per copy, surface mail, or \$33.00, airmail (overseas). Contact editor for details.

# Table of Contents

An Overview of Animal Welfare in the US Dairy Industry— <i>Franklyn B. Garry</i> .....	1
Tail Docking and Animal Welfare— <i>Pamela L. Ruegg</i> .....	24
Case Report – Diskospondylitis in Two First-calf Heifers— <i>M.D. Figueiredo, G.A. Perkins, P.A. Ospina, C. Brognano, R.M. Peters, A. deLahunta</i> .....	31
Efficacy of an <i>Arcanobacterium pyogenes-Fusobacterium necrophorum</i> Bacterin-Toxoid as an Aid in the Prevention of Liver Abscesses in Feedlot Cattle— <i>Gary Jones, H. Jayappa, Breck Hunsaker, Diane Sweeney, Vicki Rapp-Gabrielson, Terri Wasmoen, T. G. Nagaraja, Spencer Swingle, Mark Branine</i> ...	36
Efficacy of Metaphylactic Tilmicosin for Controlling Bovine Respiratory Disease in High-Risk Northern Feeder Calves— <i>Carl A. Guthrie, Karen C. Rogers, Rod A. Christmas, Gary J. Vogel, Scott B. Laudert, Gerald D. Mechor</i> .....	46
Rumen Cannulation and Utilization of a Donor Animal— <i>Shelie L. Laflin, David P. Gnad, Paul H. Walz</i> .....	54
Causes of Bovine Abortion in the North Central United States: Survey of 1618 Cases (1983-2001)— <i>Behzad Yamini, Thomas P Mullaney, Jon S Patterson, Scott D Fitzgerald, Barbara A Steficek, Frances Kennedy</i> .....	59
Case Report – Uterine Leiomyosarcoma in a Beef Cow— <i>Roberto O. Torres-Diaz, David P. Gnad, Paul H. Walz, Peter J. Chenoweth</i> .....	65
Case Report – Surgical Management of a Complicated Umbilical Abscess with Multiple Jejunal Adhesions in a 12-week-old Holstein Heifer— <i>Eli H. S. Hendrickson, Christopher B. Riley</i> .....	68
Evaluation of a Treatment Protocol for Intramammary Infections in Early Postpartum Dairy Cows Based on a Positive California Mastitis Test Result— <i>J. A. Wallace, K. Stipetic, Y. H. Schukken, R. T. Dingwell, P. Baillargeon, G. Bacic, K. E. Leslie</i> .....	72
Case Report – Herd Dermatophilosis Outbreak in a Desert Climate— <i>GM Barrington, DT Pond</i> .....	79
A Record-Keeping System for Capture of Lameness and Foot-Care Information in Cattle — <i>Jan Shearer, David Anderson, William Ayars, Ellen Belknap, Steven Berry, Charles Guard, Kent Hoblet, Ernest Hovingh, Glenn Kirksey, Alan Langill, Arlen Mills, Dale Miskimins, Jason Osterstock, Richard Price, David Prigel, Allen Roussel, Sarel van Amstel, Richard Wallace, James Wasson, Nigel Cook, Edgar F. Garrett, Douglas E. Hostetler, Lavern Schugel</i> .....	83
Bovine Viral Diarrhea (BVD): Review for Beef Cattle Veterinarians— <i>R.L. Larson, D.M. Grotelueschen, K.V. Brock, B.D. Hunsaker, R.A. Smith, R.W. Sprowls, D.S. MacGregor, G.H. Loneragan, D.A. Dargatz</i> .....	93
BVD Decision / Management Guidelines for Beef Veterinarians— <i>R.L. Larson, D.M. Grotelueschen, K.V. Brock, D.A. Dargatz, J.A. Ellis, B.D. Hunsaker, S.D. Lewis, D.S. MacGregor, R.A. Smith, R.W. Sprowls, V. Traffas</i> .....	103

## Advertisers Index

AgriLabs .....	45
Bayer HealthCare LLC .....	Front of Book
Elanco Animal Health .....	Inside Back Cover
Merial .....	22, 23
Pfizer Animal Health .....	Inside Front Cover, Front of Book, Outside Back Cover

Cover photo by *Geni Wren, Bovine Veterinarian Magazine.*

*The abstracts were translated in French by Guy Beauchamp and revised by Emile Bouchard.*

The nastier it gets, the more the cattle count on you.



We're no fair weather friend either.

Baytril® 100 (enrofloxacin) does some of its best work when the weather and bovine respiratory disease are at their worst. It kills the three toughest bacteria in a single dose, stays easy to syringe even in bone chilling conditions and gets your cattle back to work fast. Extra-label use of this product in food producing animals is prohibited. We're the antibiotic that comes through just like you.

[www.Baytril100.com](http://www.Baytril100.com)

# Baytril® 100

(enrofloxacin)

## 100 mg/mL Antimicrobial Injectable Solution

For Subcutaneous Use In Cattle Only

Not For Use In Cattle Intended For Dairy Production Or In Calves To Be Processed For Veal

### BRIEF SUMMARY:

Before using Baytril® 100 (enrofloxacin) Injectable Solution, please consult the product insert, a summary of which follows:

### CAUTION:

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Federal (U.S.A.) law prohibits the extra-label use of this drug in food producing animals.

### INDICATIONS:

Baytril® 100 (enrofloxacin) injectable solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Pasteurella haemolytica*, *Pasteurella multocida* and *Haemophilus somnus*.

### WARNING:

Animals intended for human consumption must not be slaughtered within 28 days from the last treatment.

Do not use in cattle intended for dairy production.

A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

### HUMAN WARNINGS:

**For use in animals only. Keep out of the reach of children.** Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. For customer service or to obtain product information, including Material Safety Data Sheet, call 1-800-633-3796. For medical emergencies or to report adverse reactions call 1-800-422-9874.

### PRECAUTIONS:

The effects of enrofloxacin on bovine reproductive performance, pregnancy, and lactation have not been adequately determined.

Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

Baytril® 100 contains different excipients than other Baytril® products. The safety and efficacy of this formulation in species other than cattle have not been determined.

Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures.

Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. No articular cartilage lesions were observed in the stifle joints of 23-day-old calves at 2 days and 9 days following treatment with enrofloxacin at doses up to 25 mg/kg for 15 consecutive days.

### DOSAGE ADMINISTRATION:

**Single-Dose Therapy:** Administer once, a subcutaneous dose of 7.5 - 12.5 mg/kg of body weight (3.4 - 5.7 mL/100 lb).

**Multiple-Day Therapy:** Administer daily, a subcutaneous dose of 2.5 - 5.0 mg/kg of body weight (1.1 - 2.3 mL/100 lb). Treatment should be repeated at 24-hour intervals for three days. Additional treatments may be given on days 4 and 5 to animals which have shown clinical improvement but not total recovery.

### STORAGE CONDITIONS:

Protect from direct sunlight. Do not refrigerate, freeze or store at or above 40° C (104° F). Precipitation may occur due to cold temperature. To redissolve, warm and then shake the vial.

### HOW SUPPLIED:

Baytril® 100 (enrofloxacin) Antimicrobial Injectable Solution:

Code: 08711170-023699 100 mg/mL 100 mL Bottle

Code: 08711278-032199 100 mg/mL 250 mL Bottle

For customer service or to obtain product information, including the Material Safety Data Sheet, call 1-800-633-3796. For medical emergencies or to report adverse reactions call 1-800-422-9874.

April, 2003  
08715567-80002360, R.11

Bayer HealthCare LLC  
Animal Health Division  
Shawnee Mission, Kansas 66201 U.S.A.  
NADA # 141-068, Approved by FDA

